Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

By Edson Duarte Moreira Júnior, Females United to Unilaterally Disease Reduce Endo, Ectocervical Disease. New England Journal of Medicine, 2007

1,149 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology

View Paper: https://www.semanticscholar.org/paper/a6589fb4402b9af7a9307242a1a4099d1a9ed157

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Who

In Immunology

1. Who

Citations in the corpus

• Human papillomavirus vaccines: WHO position paper. (2009, background): “Another phase III study of women aged 15e26 years followed for a mean of 3 years after the first dose found efficacy against CIN2 or CIN3 and AIS caused by HPV-16 or HPV-18 of 98% (95% CI, 86e100%) [18].”
• Cervical cancer: A global health crisis (2017, background): “Both these vaccines have been rigorously tested, initially in phase 1 and phase 2 trials and then in pivotal phase 3 trials.(35,36) These trials were performed among patient cohorts aged 15 to 26 years, and they demonstrated very high levels of type-specific antibody, which achieved very high effica”